ストックスクリーナーアプリを入手
27.97
1.19%
0.33
アフターアワーズ：
27.70
-0.27
-0.97%
前日終値:
$27.64
開ける：
$27.81
24時間の取引高:
307.93K
Relative Volume:
0.84
時価総額：
$1.33B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+9.47%
1か月 パフォーマンス:
+3.59%
6か月 パフォーマンス:
+79.99%
1年 パフォーマンス:
+73.40%
1日の値動き範囲:
$26.70
$28.56
1週間の範囲:
$25.78
$28.99
52週間の値動き範囲:
$7.13
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Compare RAPP vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
27.97 | 1.32B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-02 | 開始されました | Wells Fargo | Overweight |
| 2025-11-19 | 開始されました | BTIG Research | Buy |
| 2025-09-16 | 開始されました | Truist | Buy |
| 2025-08-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-04-08 | 開始されました | Citizens JMP | Mkt Outperform |
| 2024-07-02 | 開始されました | Jefferies | Buy |
| 2024-07-02 | 開始されました | Stifel | Buy |
| 2024-07-02 | 開始されました | TD Cowen | Buy |
すべてを表示
Rapport Therapeutics Inc (RAPP) 最新ニュース
Understanding Momentum Shifts in (RAPP) - Stock Traders Daily
RSI Check: What hedge funds are buying Rapport Therapeutics IncM&A Rumor & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
A Look At Rapport Therapeutics (RAPP) Valuation After Fresh Overweight Rating From Wells Fargo - Sahm
Rapport Therapeutics (NASDAQ:RAPP) Stock Rating Lowered by Wall Street Zen - Defense World
Rapport Therapeutics Completes Key Phase 2a Epilepsy Study for RAP-219: What Investors Should Watch Next - TipRanks
Rapport Therapeutics (NASDAQ:RAPP) Now Covered by Analysts at Wells Fargo & Company - Defense World
Wells Fargo Initiates Coverage of Rapport Therapeutics (RAPP) with Overweight Recommendation - Nasdaq
Rapport Therapeutics (RAPP): Analyst Initiates Coverage with Ove - GuruFocus
Wells Fargo Initiates Coverage on Rapport Therapeutics With Overweight Rating, $43 Price Target - marketscreener.com
Wells Fargo & Company Begins Coverage on Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Aug Final Week: What are Rapport Therapeutics Inc.’s technical support levels2025 Market WrapUp & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Whale Trades: What is the dividend yield of PMGC Holdings IncWeekly Trading Summary & Fast Gain Swing Alerts - baoquankhu1.vn
Aug Breakouts: Why is Rapport Therapeutics Inc stock going upStock Surge & Accurate Intraday Trading Signals - baoquankhu1.vn
Activity Recap: What hedge funds are buying Rapport Therapeutics IncJuly 2025 PreEarnings & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Promising Biotech with Nearly 95% Upside Potential - DirectorsTalk Interviews
Will Rapport Therapeutics Inc. stock gain from strong economyMarket Trend Review & Verified Stock Trade Ideas - mfd.ru
Should I buy Rapport Therapeutics Inc. stock nowCEO Change & Intraday High Probability Setup Alerts - mfd.ru
Is Rapport Therapeutics Inc. undervalued by DCF analysis2025 Fundamental Recap & Intraday High Probability Setup Alerts - mfd.ru
Layoff Watch: Is Rapport Therapeutics Inc gaining market shareQuarterly Portfolio Summary & Free Community Supported Trade Ideas - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (RAPP) Movement - Stock Traders Daily
Retail Surge: Is Rapport Therapeutics Inc gaining market shareWeekly Stock Summary & Expert Approved Trade Ideas - baoquankhu1.vn
Rapport Therapeutics (NASDAQ:RAPP) Upgraded to Hold at Wall Street Zen - MarketBeat
JonesTrading Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
Rapport Therapeutics, Inc. (RAPP): Investor Outlook With An 87% Potential Upside - DirectorsTalk Interviews
Rapport Therapeutics CEO Ceesay sells $285k in shares By Investing.com - Investing.com Australia
Abraham Ceesay Sells 5,833 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
Rapport Therapeutics CEO Ceesay sells $285k in shares - Investing.com
Short Interest in Rapport Therapeutics, Inc. (NASDAQ:RAPP) Expands By 20.7% - Defense World
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Short Interest Up 20.7% in December - MarketBeat
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
David Bredt Sells 8,500 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - Defense World
Rapport Therapeutics (RAPP) Is Down 7.4% After Advancing RAP-219 Toward Phase 3 In Epilepsy - Sahm
Rapport Therapeutics (NASDAQ:RAPP) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Discipline and Rules-Based Execution in RAPP Response - Stock Traders Daily
Insider Sell: David Bredt Sells 8,500 Shares of Rapport Therapeu - GuruFocus
Rapport Therapeutics (NASDAQ:RAPP) Insider David Bredt Sells 8,500 Shares - MarketBeat
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: A Biotech With 94.53% Potential Upside - DirectorsTalk Interviews
Rapport Reveals Pricing for Public Common Stock Offering - Intellectia AI
A Look At Rapport Therapeutics (RAPP) Valuation After FDA Clears Phase 3 Trial For RAP-219 - Sahm
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 6.9%Time to Sell? - MarketBeat
Rapport Therapeutics: Diversified Neurology Pipeline and Accelerated RAP-219 Development Underpin Buy Rating - TipRanks
FDA Phase 3 Green Light for RAP-219 Might Change The Case For Investing In Rapport Therapeutics (RAPP) - Sahm
Will Rapport Therapeutics Inc. stock outperform growth indexesJuly 2025 Sector Moves & Safe Capital Growth Tips - Улправда
Rapport Therapeutics, Inc. (RAPP): Investor Outlook with a Promising 84.56% Potential Upside - DirectorsTalk Interviews
Is Rapport Therapeutics Inc. stock a smart buy before Fed meeting2025 Sector Review & Free Expert Approved Momentum Trade Ideas - ulpravda.ru
Can Rapport Therapeutics Inc. stock resist market sell offsQuarterly Portfolio Review & Risk Managed Investment Entry Signals - ulpravda.ru
Form 8-KCurrent report - ADVFN
Rapport Therapeutics (RAPP) Refocuses Neurology Pipeline After RAP-219 Phase 3 Greenlight – What’s the R&D Tradeoff? - Yahoo Finance
A Quick Look at Today's Ratings for Rapport Therapeutics(RAPP.US), With a Forecast Between $40 to $56 - 富途牛牛
Rapport Therapeutics: Accelerated RAP-219 Epilepsy Path to Phase 3 and Strategic Pipeline Refocus Support Buy Rating - TipRanks
Citizens reiterates Market Outperform rating on Rapport Therapeutics stock By Investing.com - Investing.com Canada
Rapport Therapeutics Inc (RAPP) 財務データ
Rapport Therapeutics Inc (RAPP) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Rapport Therapeutics Inc (RAPP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ceesay Abraham | Chief Executive Officer |
Jan 20 '26 |
Sale |
26.11 |
5,083 |
132,737 |
25,812 |
| Bredt David | Chief Scientific Officer |
Jan 15 '26 |
Sale |
26.84 |
8,500 |
228,132 |
395,575 |
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):